# Independent SME Platform Review (2026-03-08)

## Scope and Method
This review is evidence-bound to repository artifacts only. It evaluates whether current review outcomes are trustworthy and decision-useful for near-term customer pilot and investor briefing decisions.

## Context History Timeline (Evidence-Based)
- **2026-02-25:** Technical review packet established an independent-verification posture and flagged diligence risks (metric inconsistencies, canonical-source ambiguity). Evidence: `docs/review/TECHNICAL_REVIEW_PACKET_2026-02-25.md`.
- **2026-02-26 to 2026-02-27:** Technical investor validation reported operational GO with caveats, including unresolved security-audit contradiction handling. Evidence: `docs/TECHNICAL_INVESTOR_VALIDATION_REPORT_2026-02-26.md`.
- **2026-02-27:** Security/compliance validation improved posture but explicitly left backend CVE evidence packaging incomplete for full audit assertion. Evidence: `docs/compliance/SECURITY_COMPLIANCE_VALIDATION_2026-02-27.md`.
- **2026-02-27:** Platform 360 sign-off remained **NO GO** due CI-attested evidence and CVE closeout blockers. Evidence: `docs/compliance/PLATFORM_360_SIGNOFF_2026-02-27.md`.
- **2026-03-06 to 2026-03-07:** Release-lane hardening artifacts were produced for auth/tenant regressions, manual E2E evidence, preflight stability, and RC implementation proof. Evidence: `docs/releases/v0.0.0-test/validation/security-auth-tenant-rerun-2026-03-06.md`, `docs/releases/v0.0.0-test/validation/manual-e2e-evidence-bundle-2026-03-06.md`, `docs/releases/v0.0.0-test/validation/preflight-stability-report.md`, `docs/releases/v0.0.0-test/validation/rc-implementation-proof-2026-03-07.md`.
- **2026-03-07 to 2026-03-08:** Gap-closure program moved GAP-001..004 to closed with control matrix, scorecard, and evidence index published. Evidence: `docs/compliance/GAP_REGISTER_2026-03-07.md`, `docs/compliance/REGULATORY_CONTROL_MATRIX_2026-03-07.md`, `docs/compliance/RELEASE_READINESS_SCORECARD_2026-03-07.md`, `docs/compliance/EVIDENCE_INDEX_2026-03-07.md`.
- **2026-03-08:** Regulatory and investor readiness validators report GO; pilot and ROI packs are published, but clinical safety and executive sign-offs remain explicitly in progress/pending. Evidence: `docs/releases/v0.0.0-test/validation/regulatory-readiness-report.md`, `docs/investor/INVESTOR_READINESS_REVIEW_2026-03-08.md`, `docs/releases/v0.0.0-test/GO_LIVE_PACKET.md`, `docs/releases/v0.0.0-test/validation/pilot-scorecard.md`, `docs/investor/ROI_DEFENSIBILITY_PACK_2026-03-08.md`.

## Independent Judgment: Trustworthiness and Decision-Usefulness
**Judgment:** Current outcomes are **directionally trustworthy and decision-useful for controlled planning**, but **not yet fully decision-final** for external commitments without explicit closure of pending clinical and executive sign-offs.

Why:
- Strength: control framework, gating logic, and recent closure evidence are internally coherent and reproducible.
- Limitation: some key claims remain policy/validator-driven or modeled (not yet fully observed), and several approvals are still pending in the artifacts themselves.
- Net: suitable for conditional external briefing, not for overconfident “fully de-risked” claims.

## Lens Evaluation

### 1) Security and Compliance
- **Verdict:** **Conditional GO**
- **Confidence:** **Medium-High**
- **Evidence references:**
  - `docs/compliance/REGULATORY_CONTROL_MATRIX_2026-03-07.md`
  - `docs/compliance/RELEASE_READINESS_SCORECARD_2026-03-07.md`
  - `docs/compliance/GAP_REGISTER_2026-03-07.md`
  - `docs/compliance/ACCESS_REVIEW_2026-03-07.md`
  - `docs/compliance/THIRD_PARTY_RISK_REGISTER_2026-03-07.md`
  - `docs/compliance/SECURITY_COMPLIANCE_VALIDATION_2026-02-27.md`
  - `test-results/upstream-ci-gates-2026-03-07.log`
- **Top residual risks:**
  - Historical backend CVE evidence packaging and SOC2 audit-pack completeness were previously called incomplete; current lane artifacts show control PASS, but evidence-chain continuity to external-audit grade needs explicit reconciliation.
  - Evidence quality relies on internal validators and pattern checks; independent re-execution cadence must continue to preserve trust.

### 2) Clinical Safety Readiness
- **Verdict:** **Conditional GO**
- **Confidence:** **Medium**
- **Evidence references:**
  - `docs/releases/v0.0.0-test/safety/SAFETY_CASE_CARE_GAP_PRIORITIZATION.md`
  - `docs/releases/v0.0.0-test/safety/SAFETY_CASE_REALTIME_INTERVENTION_ALERTING.md`
  - `docs/releases/v0.0.0-test/safety/SAFETY_CASE_REVENUE_CYCLE_DENIAL_PREVENTION.md`
  - `docs/releases/v0.0.0-test/recommendations/RECOMMENDATION_CLINICAL_SAFETY.md`
  - `docs/releases/v0.0.0-test/GO_LIVE_PACKET.md`
- **Top residual risks:**
  - All three safety cases list approvals as pending; this is a material governance gap for clinical-readiness assertions.
  - Safety monitoring thresholds are defined, but operational proof of sustained monitoring performance in live pilot conditions is still limited.

### 3) Operational Reliability
- **Verdict:** **GO (Controlled Pilot Scope)**
- **Confidence:** **Medium-High**
- **Evidence references:**
  - `docs/releases/v0.0.0-test/validation/preflight-stability-report.md`
  - `docs/compliance/DR_TEST_RESULTS_2026-03-07.md`
  - `docs/releases/v0.0.0-test/validation/rc-implementation-proof-2026-03-07.md`
  - `docs/releases/v0.0.0-test/validation/manual-e2e-evidence-bundle-2026-03-06.md`
  - `docs/releases/v0.0.0-test/validation/evidence-freshness-report.md`
- **Top residual risks:**
  - Preflight report includes extra containers in degraded/restarting states outside the required gate set; scope boundary is explicit, but operational blast-radius assumptions should be stated in customer briefings.
  - Manual E2E bundle still carries at least one non-blocking medium issue; keep it visible rather than implied resolved.

### 4) Investor Diligence Quality
- **Verdict:** **Conditional GO**
- **Confidence:** **Medium**
- **Evidence references:**
  - `docs/investor/INVESTOR_READINESS_REVIEW_2026-03-08.md`
  - `docs/investor/CURRENT_READINESS_ONE_PAGER_2026-03-08.md`
  - `docs/investor/ROI_DEFENSIBILITY_PACK_2026-03-08.md`
  - `docs/releases/v0.0.0-test/validation/pilot-scorecard.md`
  - `docs/TECHNICAL_INVESTOR_VALIDATION_REPORT_2026-02-26.md`
  - `docs/review/TECHNICAL_REVIEW_PACKET_2026-02-25.md`
- **Top residual risks:**
  - ROI and pilot KPI values are explicitly modeled/early baseline and not yet mature observed-outcome evidence.
  - Sign-off fields remain pending in pilot/commercial readiness artifacts.
  - Historical caveat on security-audit contradiction reconciliation should be carried forward transparently in investor narrative.

## Final Recommendation

### Customer Pilot Briefing Readiness
**Recommendation:** **Ready for controlled pilot briefing (Conditional GO).**

Conditions for responsible briefing language:
- Describe pilot as controlled and monitored, not fully de-risked.
- Explicitly disclose pending clinical safety approvals and active monitoring commitments.
- Present KPI/ROI values as baseline/model-backed, not final realized performance.

### Investor Briefing Readiness
**Recommendation:** **Ready for evidence-backed investor briefing (Conditional GO).**

Conditions for responsible briefing language:
- Use control/evidence maturity as the lead claim.
- Avoid presenting modeled ROI as validated realized outcome.
- Include residual-risk and closure status slide (clinical approvals, evidence-chain reconciliation, ongoing cadence).

## What Must Be True in the Next 7 Days
1. Clinical safety owner, medical director, engineering owner, and compliance owner approvals are completed for all three safety cases.
2. Pilot scorecard and ROI pack are refreshed with observed week-over-week values, with confidence bands retained.
3. A single reconciled security/compliance status note explicitly closes or scopes historical CVE/SOC2 evidence contradictions.
4. Go-live packet approval fields move from pending to signed with named accountable roles.
5. Release validators are rerun after any material change; artifacts remain fresh within stated cadence windows.
6. Customer and investor brief decks include a transparent residual-risk section aligned to the latest gap/control artifacts.
